- Nov 27 2017
Key Patent Approval
PDS Biotechnology Announces US Approval of Another Key Patent in its Patent Portfolio
PDS Biotechnology Corporation, a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced approval of its patent covering stimulation of an immune response by enantiomers of cationic lipids by the US Patent and Trademark Office.
PDS is pioneering the use of novel cationic lipids in safe and highly effective immunotherapies. Major obstacles facing the development of effective immunotherapies, such as the lack of induction of tumor-specific CD8+ T-cells and the need to overcome cancer tumor immune-suppressive microenvironments, are effectively addressed using PDS’s Versamune® cationic lipid technology platform.
PDS’s research and development programs were the first to discover and report enantiomeric specificity of the immune response as it pertains to certain cationic lipids. These pure lipid enantiomers activate important immunological signaling pathways, without inducing the toxicities typically associated with other means of activating the human immune system.
The new US patent, covering stimulation of an immune response by lipid enantiomers, has also been issued in multiple other countries. This US approval follows previous PDS patent approvals in the US and other countries covering its initial inventions related to general compositions and use of cationic lipids to induce an immune response.
Versamune® is a novel clinical stage, synthetic lipid-based immunotherapy platform. The Versamune®-based products which are administered by sub-cutaneous injection, have been demonstrated to facilitate superior anti-tumor efficacy due to the platform’s multi-functional mechanism of action. The platform provides potent activation of the type I interferon genes. The mechanism of action also involves effective presentation of the tumor antigens via the MHC Class I pathway. Both mechanisms together promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ T-cells. This result, as well as excellent safety were confirmed in a Phase 1/2a human clinical trial. The Versamune® approach also inhibits immune-suppressive regulatory T-cells within the tumors, further facilitating the anti-tumor efficacy of the products. The Versamune® platform is now being applied to the development of multiple Phase 2b clinical-stage cancer products, including both early and late-stage cancer indications, as well as combinations with other successful immuno-oncology approaches such as checkpoint inhibitors.
About PDS Biotechnology
PDS Biotechnology is a private biopharmaceutical company with a growing pipeline of simpler, safer, and more effective clinical-stage immunotherapies to treat various early-stage and late-stage cancers. PDS is progressing a pipeline of immuno-oncology products to treat various cancers including, head and neck cancer, cervical cancer, prostate cancer, breast cancer etc. into phase 2 human clinical trials. This pipeline progression is based on successful demonstration of safety, and strong induction of antigen-specific CD8+ T-cell responses in a recently completed phase 1/2a human clinical trial.